Bristol Myers: Deucravacitinib Shows Superiority to Placebo, Otezla in Phase 3 Psoriasis Study

By Colin Kellaher

Bristol Myers Squibb Co. on Tuesday said the first pivotal Phase 3 study evaluating deucravacitinib for the treatment of moderate to severe plaque psoriasis met both co-primary endpoints and multiple key secondary endpoints.

The New York biopharmaceutical company said deucravacitinib showed superiority to placebo and to Amgen Inc.'s blockbuster Otezla after 16 weeks of treatment.

Bristol Myers said the overall safety profile of deucravacitinib was consistent with previous Phase 2 results, adding that it will share detailed results of the study at a later date.

The study is the first of two global Phase 3 trials designed to evaluate safety and efficacy of deucravacitinib compared with placebo and Otezla in patients with moderate to severe plaque psoriasis. Bristol Myers said it expects results from the second study in the first quarter of 2021.

Amgen last year bought Otezla from Celgene Corp. for $13.4 billion in a deal that paved the regulatory way for Bristol Myers to complete its $74 billion acquisition of Celgene.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

November 03, 2020 07:50 ET (12:50 GMT)

Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024